

# Eribulin

Solution for Injection

MADE IN GERMANY



0.88 mg  
2 ml

1.32 mg  
3 ml

## Eribulin EVER Pharma is available in both strengths: 2 ml and 3 ml

Eribulin mesilate is a chemotherapy drug indicated for advanced or metastatic breast cancer in patients who have progressed after prior treatment. It is also approved for unresectable liposarcoma in adults previously treated with anthracycline-based therapy.

- **Available in 2 presentations** – providing greater flexibility and convenience when preparing patient specific doses
- **All vial sizes come in CytoWrap®** – for safer handling and transportation



[www.everpharma.com](http://www.everpharma.com)



<b>Indications</b>	<p>Eribulin EVER Pharma is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.</p> <p>Eribulin EVER Pharma is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.</p>
<b>Active Ingredient</b>	Eribulin mesilate
<b>Excipients</b>	Ethanol anhydrous, Hydrochloric acid, Sodium hydroxide, Water for injections
<b>Presentations</b>	<ul style="list-style-type: none"><li>■ <b>0.88 mg/2 ml</b> solution for injection</li><li>■ <b>1.32 mg/3 ml</b> solution for injection</li></ul>
<b>Strengths</b>	Each 1 ml contains eribulin mesilate equivalent to 0.44 mg eribulin.
<b>Stability</b>	<ul style="list-style-type: none"><li>■ <b>Unopened:</b> 36 months. Do not store above 30°C.</li><li>■ <b>In-use (undiluted):</b> 8 hours at 15-25°C (ambient lightning) and up to 32 hours at 2-8°C</li><li>■ <b>After dilution:</b> 8 hours at 15-25°C (ambient lightning) and up to 48 hours at 2-8°C</li></ul>
<b>Primary Packaging</b>	Type I colourless glass 5 ml vial, closed with a fluoropolymer-coated bromobutyl rubber stopper sealed with an aluminium crimp covered with a plastic flip-off cap
<b>Pack sizes</b>	1 or 6 vials per pack. Vials may or may not be sheathed in a protective sleeve.
<b>Density</b>	0.99 g/cm <sup>3</sup>



Plastic sleeving for safer handling

**Eribulin EVER Pharma 0.44 mg/ml solution for injection.** Composition: One ml contains eribulin mesilate equivalent to 0.44 mg eribulin. List of excipients: Ethanol anhydrous, Water for injections, Hydrochloric acid, Sodium hydroxide. Therapeutic indications: For the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments. For the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Breast-feeding. Side effects: very common: Neutropenia, Leukopenia, Anaemia, Decreased appetite, Peripheral neuropathy, Headache, Dyspnoea, Cough, Nausea, Constipation, Diarrhoea, Vomiting, Alopecia, Arthralgia and myalgia, Back pain, Pain in extremity, Fatigue/Asthenia, Pyrexia, Weight decreased. common: Urinary tract infection, Pneumonia, Oral candidiasis, Oral herpes, Upper respiratory tract infection, Nasopharyngitis, Rhinitis, Herpes zoster, Lymphopenia, Febrile neutropenia, Thrombocytopenia, Hypokalaemia, Hypomagnesaemia, Dehydration, Insomnia, Depression, Dysgeusia, Dizziness, Hypoaesthesia, Lethargy, Neurotoxicity, Lacrimation increased, Conjunctivitis, Vertigo, Tinnitus, Tachycardia, Hot flush, Pulmonary embolism, Oropharyngeal pain, Epistaxis, Rhinorrhoea, Abdominal pain, Stomatitis, Dry mouth Dyspepsia, Gastrooesophageal reflux disease, Abdominal distension, Aspartate aminotransferase increased, Alanine aminotransferase increased, Gamma glutamyl transferase increased, Hyperbilirubinaemia, Rash, Pruritus, Nail disorder, Night sweats, Dry skin, Erythema, Hyperhidrosis, Palmar plantar erythrodysesthesia, Bone pain, Muscle spasms, Musculoskeletal pain, Musculoskeletal chest pain, Muscular weakness, Dysuria, Mucosal Inflammation, Peripheral oedema, Pain, Chills, Chest pain, Influenza like illness. uncommon: Sepsis, Neutropenic sepsis, Septic Shock, Deep vein thrombosis, Interstitial lung disease, Mouth ulceration, Pancreatitis, Hepatotoxicity, Angioedema, Haematuria, Proteinuria, Renal failure. rare or unknown: Disseminated intravascular coagulation, Stevens-Johnson syndrome/ Toxic epidermal necrolysis. More information available in the summary of product characteristics. Only available on prescription. Last update: March 2024. Marketing Authorisation Holder: EVER Valinject GmbH, Oberburgau 3, 4866 Unterach am Attersee, Austria. Eribulin EVER Pharma is available after patent expiry.